119165-68-3

Basic information

• Product Name: 2-(1H-IMIDAZOL-2-YL)-PYRAZINE
• Synonyms: 2-(1H-IMIDAZOL-2-YL)-PYRAZINE;2-(1H-2-IMidazolyl)pyrazine
• CAS NO: 119165-68-3
• Molecular Formula: C₇H₆N₄
• Molecular Weight: 146.14934
• Mol File: 119165-68-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(1H-IMIDAZOL-2-YL)-PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-IMIDAZOL-2-YL)-PYRAZINE(119165-68-3)
• EPA Substance Registry System: 2-(1H-IMIDAZOL-2-YL)-PYRAZINE(119165-68-3)

Safety Data

• Hazardous Substances Data: 119165-68-3(Hazardous Substances Data)

Usage

General Description

2-(1H-IMIDAZOL-2-YL)-PYRAZINE is a chemical compound that consists of a Pyrazine core with an Imidazole group attached at the 2nd position. Pyrazine is an organic compound with the formula C4H4N2, characterized by a six-membered ring with two nitrogen atoms and four carbon atoms. Imidazole, on the other hand, is a five-membered planar ring, which includes two nitrogen atoms and three carbon atoms. 2-(1H-IMIDAZOL-2-YL)-PYRAZINE might be used in various applications including pharmaceutical and chemical research, however, its specific uses and properties would largely depend on the context wherein it is applied.

Upstream product

• 19847-12-2 2-pyrazine carbonitrile 
• 22483-09-6 2,2-dimethoxyethylamine 
• 645-36-3 2,2-diethoxy-ethanamine 

Downstream Products

• 1384461-52-2 (4aS,5R,7aS)-7a-(2-fluoro-5-(2-(pyrazin-2-yl)-1H-imidazol-5-yl)phenyl)-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-2-amine 

Relevant articles and documents

Switching the Spin-Crossover Phenomenon by Ligand Design on Imidazole-Diazineiron(II) Complexes

The iron(II) complexes of two structural isomers of 2-(1H-imidazol-2-yl)diazine reveal how ligand design can be a successful strategy to control the electronic and magnetic properties of complexes by fine-tuning their ligand field. The two isomers only differ in the position of a single diazinic nitrogen atom, having either a pyrazine (Z) or a pyrimidine (M) moiety. However, [Fe(M)3](ClO4)2 is a spin-crossover complex with a spin transition at 241 K, whereas [Fe(Z)3](ClO4)2 has a stable magnetic behavior between 2 and 300 K. This is corroborated by temperature-dependent M?ssbauer spectra showing the presence of a quintet and a singlet state in equilibrium. The temperature-dependent single-crystal X-ray diffraction results relate the spin-crossover observed in [Fe(M)3](ClO4)2 to changes in the bond distances and angles of the coordination sphere of iron(II), hinting at a stronger σ donation of ligand Z in comparison to ligand M. The UV/vis spectra of both complexes are solved by means of the multiconfigurational wave-function-based method CASPT2 and confirm their different spin multiplicities at room temperature, as observed in the M?ssbauer spectra. Calculations show larger stabilization of the singlet state in [Fe(Z)3]2+ than in [Fe(M)3]2+, stemming from the slightly stronger ligand field of the former (506 cm-1 in the singlet). This relatively weak effect is indeed capable of changing the spin multiplicity of the complexes and causes the appearance of the spin transition in the M complex.

Fused Aminodihydrothiazine Derivatives

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C1-6alkyl, C2-3alkenyl, C2-3alkynyl,C-6alkoxy, C3-6cycloalkoxy and pyrazine, where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by Aβ and typified by Alzheimer-type dementia.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.